Drugs / LY3526318
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT05580250 | Nov → Dec 2022 | — | Eli Lilly and Company | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04682119 | Dec 2020 → Apr 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04183283 | Dec 2019 → Feb 2020 | — | Eli Lilly and Company | Completed | Met primary |
| Phase 1 | NCT03977974 | Jun 2019 → Mar 2020 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 24 trials · 3 missed | ||||||
| Phase 2 | NCT05177094 | Jan → Oct 2022 | diabetic neuropathy | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT05086289 | Oct 2021 → Jun 2022 | chronic pain syndrome | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT05080660 | Oct 2021 → Jun 2022 | osteoarthritis, knee | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT05986292 | Jan 2020 → Apr 2027 expected | chronic pain syndrome, diabetic neuropathy, osteoarthritis, knee | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3526318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682119 ↗ |
| Route | Oral | “Administered orally” NCT03977974 ↗ |